SENATE DOCKET, NO. 1595 FILED ON: 1/19/2023
SENATE . . . . . . . . . . . . . . No. 1363
|
The Commonwealth of Massachusetts
_________________
PRESENTED BY:
Ryan C. Fattman
_________________
To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:
The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying resolve:
Resolve establishing a special commission to broaden the availability of naloxone.
_______________
PETITION OF:
Name: | District/Address: |
Ryan C. Fattman | Worcester and Hampden |
SENATE DOCKET, NO. 1595 FILED ON: 1/19/2023
SENATE . . . . . . . . . . . . . . No. 1363
By Mr. Fattman, a petition (accompanied by resolve, Senate, No. 1363) of Ryan C. Fattman that provisions be made for an investigation and study by a special commission (including members of the General Court) relative to broadening the availability of naloxone without a prescription. Public Health. |
[SIMILAR MATTER FILED IN PREVIOUS SESSION
SEE SENATE, NO. 1431 OF 2021-2022.]
The Commonwealth of Massachusetts
_______________
In the One Hundred and Ninety-Third General Court
(2023-2024)
_______________
Resolve establishing a special commission to broaden the availability of naloxone.
Resolved, that a special commission to study the alternative and develop recommendations to broaden the availability of naloxone without prescription, including but not limited to recommendations on the standing order process, the collaborative practice agreement process, and/or legislative recommendations.
The special commission shall consist of: the secretary of health and human services or their designee, who shall serve as chair; the commissioner of the division of insurance or their designee; three members to be appointed by the governor, which shall include; one person who is a prescribing physician, one person who is a stakeholder within a retail pharmacy company, and one member of the general citizenry impacted by the opiate epidemic; two members of the house of representatives, one of whom to be appointed by the minority leader; two members of the senate, one of whom to be appointed by the minority leader; the director of the board of pharmacy or their designee; the director of the bureau of substance abuse services or their designee; provided, however, that the first meeting of the commission shall take place not later than January 1, 2025.
The special commission shall submit its recommendations, together with drafts of any legislation, to the clerks of the house of representatives and the senate, the chairs of the joint committee on mental health and substance abuse not later than May 1, 2025.